ONESOURCE Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
OneSource Specialty Pharma reported strong Q2 FY27 results with 37% YoY revenue growth to over INR5bn, 53% YoY EBITDA growth, and 400 bps QoQ margin expansion. Growth was driven by new DDC capacity, strong semaglutide demand, and new customer wins. Management reaffirmed FY28 guidance of $400mn revenue and $160mn EBITDA, with all three DDC lines to be operational. Biologics is emerging as a key growth pillar. Key risks include geopolitical disruptions and qualification timelines.
Management Tone
- Prepared Remarks: Great — Prepared remarks highlighted strong sequential and YoY growth, capacity expansion progress, new customer wins, and reaffirmed guidance with confident tone.
- Q&A Session: Good — Analysts asked about capacity utilization, ramp-up, guidance, and margin drivers; management provided detailed and confident responses. Some questions on batch sizes and timing were handled with clarity.
Revenue Growth Drivers
- Additional DDC capacity (Line 2) enabling commercial and MSA revenue
- Strong demand for semaglutide and other products across markets
- New customer wins and new launches
Growth vs Margin Focus
Management emphasized growth through capacity expansion and new launches while also highlighting margin expansion from operating leverage.
About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (ONESOURCE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.